- 作者：Azusa Hasegawa ; D.D.S. ; Ph.D.&lowast ; ; Jun-Etsu Mizoe ; M.D. ; Ph.D.&lowast ; ; junetsumizoe@gmail.com ; Hirohiko Tsujii ; M.D. ; Ph.D.&lowast ; ; Tadashi Kamada ; M.D. ; Ph.D.&lowast ; ; Keiichi Jingu ; M.D. ; Ph.D.&lowast ; ; Yasuo Iwadate ; M.D. ; Ph.D.&dagger ; ; Youichi Nakazato ; M.D. ; Ph.D.&Dagger ; ; Masao Matsutani ; M.D. ; Ph.D.§ ; ; Kintomo Takakura ; M.D. ; Ph.D.¶ ; ; Organizing Committee of the Central Nervous System Tumor Working Group
- 关键词：Carbon ion radiotherapy ; Diffuse astrocytomas ; Dose escalation study ; High-LET radiotherapy ; Phase I/II clinical trial
- 刊名：International Journal of Radiation Oncology*Biology*Physics
- 出版年：2012
- 出版时间：1 May, 2012
- 年：2012
- 卷：83
- 期：1
- 页码：100-106
- 全文大小：204 K
Purpose
To assess outcomes of carbon ion radiotherapy for diffuse astrocytomas in adults.Methods and Materials
Between October 1994 and February 2002, 14 patients with diffuse astrocytoma, identified as eligible for carbon ion radiotherapy, were enrolled in a phase I/II clinical trial. Carbon ion radiotherapy was administered in 24 fractions over 6 weeks. The normal tissue morbidity was monitored carefully, and the carbon ion dose was escalated from 50.4 Gy equivalent (GyE) to 55.2 GyE. Patients were divided into two groups according to their carbon ion doses: a low-dose group in which 2 patients were irradiated with 46.2 GyE and 7 patients were irradiated with 50.4 GyE, and a high-dose group in which 5 patients were irradiated with 55.2 GyE.
Results
Toxicities were within acceptable limits, and none of the patients developed Grade 3 or higher acute or late reactions. The median progression-free survival (PFS) time was 18 months for the low-dose group and 91 months for the high-dose group (p = 0.0030). The median overall survival (OS) time was 28 months for the low-dose group and not reached for the high-dose group (p = 0.0208).
Conclusion
High-dose group patients showed significant improvement in PFS and OS rates compared to those in the low-dose group, and both dose groups showed acceptable toxicity.